Analysis of lung air from patients with bronchogenic carcinoma and controls using gas chromatography-mass spectrometry

Preti, George; Labows, John N.; Kostelc, James G.; Aldinger, S B; Daniele, Ronald P.

doi:10.1016/s0378-4347(00)80627-1

Cited by 181 publications

(136 citation statements)

References 13 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…A number of studies have been carried out in order to characterize substances in breath samples from patients with and without lung cancer (O'Neill et al, 1988;Petri et al, 1988;Phillips et al, 1999a,b;Deng et al, 2004a;Poli et al, 2005;Yu et al, 2005;Phillips et al, 2006). In 1988, two groups of researchers separately reported some VOCs as potential lung cancer marking substances (O'Neill et al, 1988;Petri et al, 1988). Later, Phillips et al (1999a,b) suggested a combination of 22 breath VOCs, including methylated alkanes and benzene derivatives, for detection of lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Human exhaled air analytics: biomarkers of diseases

Buszewski

Kęsy

Ligor

et al. 2007

Biomedical Chromatography

678

531

View full text Add to dashboard Cite

Over the last few years, breath analysis for the routine monitoring of metabolic disorders has attracted a considerable amount of scientific interest, especially since breath sampling is a non-invasive technique, totally painless and agreeable to patients. The investigation of human breath samples with various analytical methods has shown a correlation between the concentration patterns of volatile organic compounds (VOCs) and the occurrence of certain diseases. It has been demonstrated that modern analytical instruments allow the determination of many compounds found in human breath both in normal and anomalous concentrations. The composition of exhaled breath in patients with, for example, lung cancer, inflammatory lung disease, hepatic or renal dysfunction and diabetes contains valuable information. Furthermore, the detection and quantification of oxidative stress, and its monitoring during surgery based on composition of exhaled breath, have made considerable progress. This paper gives an overview of the analytical techniques used for sample collection, preconcentration and analysis of human breath composition. The diagnostic potential of different disease-marking substances in human breath for a selection of diseases and the clinical applications of breath analysis are discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Human exhaled air analytics: biomarkers of diseases

Buszewski

Kęsy

Ligor

et al. 2007

Biomedical Chromatography

678

531

View full text Add to dashboard Cite

show abstract

“…Their model demonstrated 93% accuracy in separating the two groups. Three years later, two other groups confirmed their findings by using a different set of VOCs for discrimination of lung cancer patients from control subjects, but both studies had a relatively small sample size [33,34]. The first report involving a larger number of subjects was published in 1999 by PHILLIPS et al [27].…”

mentioning

confidence: 99%

Exhaled biomarkers in lung cancer

Horváth

Lázár

Gyulai

et al. 2009

European Respiratory Journal

239

206

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death. Results of therapeutic interventions are particularly discouraging when the disease is discovered in an advanced stage. Early diagnosis is limited by the fact that the disease usually develops asymptomatically and available screening methods do not fulfil the requirements for reliable discrimination between patients with lung cancer and subjects not suffering from the disease. Breath sampling is completely noninvasive and provides a potentially useful approach to screening lung cancer. Exhaled biomarkers contain both volatile and nonvolatile molecules. The profile of volatile organic compounds is different in patients with lung cancer than in control subjects. In exhaled breath condensate, the proteomic profile of breath from cancer patients differs from that of healthy smokers. We reviewed the scientific evidence demonstrating that a unique chemical signature can be detected in the breath of patients with lung cancer and that the exhaled breath biomarker profile could aid clinical decision making.KEYWORDS: Biomarker, electronic nose, exhaled breath, exhaled breath condensate, lung cancer, smell L ung cancer is the leading cause of global cancer death in both males and females. According to the most recent projection of global mortality, by 2030 it will emerge as the third and the fifth leading cause of death in highand middle-income countries, respectively [1,2]. Figures on disease outcome measures are very discouraging as even with the most advanced treatment strategies ,86% of lung cancer patients die within 5 yrs of diagnosis. With early detection and treatment, however, the 5-yr survival rate improves dramatically from 20% in patients with stage III lung cancer to 70% in patients with stage I disease [3]. Researchers, therefore, have sought out screening tests to detect lung cancer in the earliest stages and several promising new approaches have been proposed for this purpose, such as computer-assisted image analysis of chest radiographs, spiral computed tomography (CT) scanning, PCR-based assays of sputum and fluorescence bronchoscopy [4][5][6][7].Breath chemical tests have a broad spectrum of applications ranging from the US Food and Drug Administration-approved exhaled nitric oxide fraction (FeNO) measurement to monitor the effect of anti-inflammatory treatment in asthma, to volatile organic compound (VOC) determination and nonvolatile biomarker profiling in the cooled breath sample called exhaled breath condensate (EBC) [8][9][10][11]. Being completely noninvasive, sampling of the breath allows clinicians and researchers to assess different body functions in a flexible manner. Breath collection can be performed even in very severe patients and also repeated within short intervals. Therefore, breath testing is considered to be a potentially ideal candidate for screening purposes. Besides widely known constituents such as nitrogen, oxygen, carbon dioxide, inert gases and water vapour, exhaled breath also consists of thousands of volatile and nonv...

show abstract

“…New molecular markers that are indicators of specific diseases, both infectious and noninfectious, are being increasingly revealed by new scientific research. Some examples of these volatile molecular biomarkers (or bioindicators) of disease and physiological disorders, reported hitherto by various researchers, are summarized in Manolis, 1983;Gordon et al, 1985;Preti et al, 1988;Phillips et al, 1999bPhillips et al, , 2003a Analysis of expired human breath is considered particularly valuable because it can be monitored noninvasively (without causing physical damage to patients), yet provide information about the chemical and physiological state of the entire body. The reason that information about the physical health of the entire body is possible by the analysis of expired breath is because most volatile metabolites of infectious agents of disease, or those produced from abnormal tissues, are eventually eliminated from the body through the lungs, often soon after being formed within diseased tissues.…”

Section: Discovery Of Bioindicators Of Diseasementioning

confidence: 99%

Future Applications of Electronic-Nose Technologies in Healthcare and Biomedicine

Wilson¹

2011

Wide Spectra of Quality Control

View full text Add to dashboard Cite

Analysis of lung air from patients with bronchogenic carcinoma and controls using gas chromatography-mass spectrometry

Cited by 181 publications

References 13 publications

Human exhaled air analytics: biomarkers of diseases

Human exhaled air analytics: biomarkers of diseases

Exhaled biomarkers in lung cancer

Future Applications of Electronic-Nose Technologies in Healthcare and Biomedicine

Contact Info

Product

Resources

About